From the Health Management Center, The Third Xiangya Hospital, Central South University, 138 Tongzipo Road, Changsha, Hunan 410013, China.
Center for Experimental Medicine, The Third Xiangya Hospital, Central South University, 138 Tongzipo Road, Changsha, Hunan 410013, China.
QJM. 2023 May 27;116(5):365-374. doi: 10.1093/qjmed/hcad010.
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease, and genetic contributors exert a significant role in the complicated pathogenesis. Identification of the genetic causes in ALS families could be valuable for early diagnosis and management. The development of potential drugs for patients with genetic defects will shed new light on ALS therapy.
To identify causative variants in three Chinese families with familial ALS (FALS), reveal the pathogenic mechanism and look for the targeted drug for ALS.
Whole-exome sequencing and bioinformatics were used to perform genetic analysis of the ALS families. Functional analysis was performed to study the variants' function and search for potential drug targets.
Three heterozygous missense variants of the superoxide dismutase 1 gene (SOD1) were identified in families with FALS. The clinical manifestations of these patients include spinal onset, predominant lower motor neurons presentation and absence of cognitive involvement. Functional analysis showed that all three SOD1 variants led to increased reactive oxygen species (ROS) levels, reduced cell viability and formation of cytoplasmic aggregates. Remarkably, the decreased cell viability induced by variants was rescued after treatment with the ROS inhibitor N-acetylcysteine.
This study identified three SOD1 variants in three families with FALS. The variant SOD1 toxicity was associated with oxidative damage and aggregation, and N-acetylcysteine could rescue the decreased cell viability induced by these variants. Our findings support a pathogenic role for ROS in SOD1 deficiencies and provide a potential drug N-acetylcysteine for ALS therapy, especially in SOD1 patients with limb onset.
肌萎缩侧索硬化症(ALS)是一种神经退行性疾病,遗传因素在其复杂的发病机制中发挥着重要作用。在 ALS 家族中鉴定遗传原因对于早期诊断和管理可能具有重要价值。为具有遗传缺陷的患者开发潜在药物将为 ALS 治疗带来新的希望。
在三个中国家族性肌萎缩侧索硬化症(FALS)家系中鉴定致病变异,揭示其发病机制,并寻找针对 ALS 的靶向药物。
采用外显子组测序和生物信息学方法对 ALS 家系进行遗传分析。进行功能分析以研究变异的功能并寻找潜在的药物靶点。
在 FALS 家系中鉴定出三个超氧化物歧化酶 1 基因(SOD1)的杂合错义变异。这些患者的临床表现包括脊髓发病、主要为下运动神经元表现和无认知受累。功能分析表明,所有三种 SOD1 变异均导致活性氧(ROS)水平升高、细胞活力降低和细胞质聚集体形成。值得注意的是,用 ROS 抑制剂 N-乙酰半胱氨酸处理后,变异引起的细胞活力降低得到了挽救。
本研究在三个 FALS 家系中鉴定出三个 SOD1 变异。变异 SOD1 的毒性与氧化损伤和聚集有关,N-乙酰半胱氨酸可以挽救这些变异引起的细胞活力降低。我们的研究结果支持 ROS 在 SOD1 缺乏中的致病作用,并为 ALS 治疗提供了一种潜在药物 N-乙酰半胱氨酸,特别是在具有肢体发病的 SOD1 患者中。